PARATEK PHARMACEUTICALS, INC. FILES (8-K) Disclosing Regulation FD Disclosure, Financial Statements and Exhibits

Edgar Glimpses |

Item 7.01 Regulation FD Disclosure.

On , Paratek Pharmaceuticals, Inc., or the Company, issued a press release announcing positive top-line results from a Phase 3 clinical study of its broad-spectrum investigational antibiotic, omadacycline, for the treatment of acute bacterial skin and skin structure infections. This study represents the third positive Phase 3 registration study of omadacycline, which will be used to support marketing applications to the United States Food and Drug Administration and the European Medicines Agency. A copy of this press release is attached hereto as Exhibit 99.1.



The Company plans to host a webcast and conference call related to the top-line data at on . The presentation and a link to the webcast will be available under "Events and Presentations" in the Investor Relations section of the Company's website at www.paratekpharma.com.

The information in this Current Report on Form 8-K is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information contained herein or the presentation materials or webcast referenced herein.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits






Exhibit No.                               Description

99.1          Press Release of Paratek Pharmaceuticals, Inc. dated .










--------------------------------------------------------------------------------

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Margaux Resources Ltd.

Margaux Resources Ltd is a Calgary based resource company. The Company is focused on its Jersey Emeral Tungsten-Zinc property located in the southeast portion of British Columbia.

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…